4.6 Article

Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients

Journal

BASIC RESEARCH IN CARDIOLOGY
Volume 117, Issue 1, Pages -

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00395-022-00918-7

Keywords

Anthracyclin-induced cardiotoxicity (ACT); Induced pluripotent stem cells (iPSC); Cardiomyocytes; Cardiac fibroblasts; Heart failure; Doxorubicin

Funding

  1. Bundesministerium fur Bildung und Forschung (BMBF) grant e: Bio -Modul II -Verbundprojekt [031L0075C]
  2. German Center for Cardiovascular Research (DZHK) [B14031KSB]
  3. Heidenreich von Siebold Program from the University Medical Center Gottingen
  4. German Heart Foundation/German Foundation of Heart Research [F/38/18]
  5. Else Kroner-Fresenius-Stiftung Foundation [2017-A137]
  6. Informatics for Life, Klaus Tschira Stiftung - German Society of Internal Medicine [1816]
  7. Deutsche Forschungsgemeinschaft
  8. British Heart Foundation
  9. Department of Health via a National Institute for Health Research (NIHR) Biomedical Research Centre award
  10. King's College London
  11. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence [Strategy-EXC 2067/1-390729940]

Ask authors/readers for more resources

This study developed a patient-specific stem cell model to investigate DOX-induced cardiac dysfunction. The results showed that DOX-induced stress led to arrhythmogenic events and contractile dysfunction, ultimately resulting in heart failure.
Cancer therapies with anthracyclines have been shown to induce cardiovascular complications. The aims of this study were to establish an in vitro induced pluripotent stem cell model (iPSC) of anthracycline-induced cardiotoxicity (ACT) from patients with an aggressive form of B-cell lymphoma and to examine whether doxorubicin (DOX)-treated ACT-iPSC cardiomyocytes (CM) can recapitulate the clinical features exhibited by patients, and thus help uncover a DOX-dependent pathomechanism. ACT-iPSC CM generated from individuals with CD20(+) B-cell lymphoma who had received high doses of DOX and suffered cardiac dysfunction were studied and compared to control-iPSC CM from cancer survivors without cardiac symptoms. In cellular studies, ACT-iPSC CM were persistently more susceptible to DOX toxicity including augmented disorganized myofilament structure, changed mitochondrial shape, and increased apoptotic events. Consistently, ACT-iPSC CM and cardiac fibroblasts isolated from fibrotic human ACT myocardium exhibited higher DOX-dependent reactive oxygen species. In functional studies, Ca2+ transient amplitude of ACT-iPSC CM was reduced compared to control cells, and diastolic sarcoplasmic reticulum Ca2+ leak was DOX-dependently increased. This could be explained by overactive CaMKII delta in ACT CM. Together with DOX-dependent augmented proarrhythmic cellular triggers and prolonged action potentials in ACT CM, this suggests a cellular link to arrhythmogenic events and contractile dysfunction especially found in ACT engineered human myocardium. CamKII delta inhibition prevented proarrhythmic triggers in ACT. In contrast, control CM upregulated SERCA2a expression in a DOX-dependent manner, possibly to avoid heart failure conditions. In conclusion, we developed the first human patient-specific stem cell model of DOX-induced cardiac dysfunction from patients with B-cell lymphoma. Our results suggest that DOX-induced stress resulted in arrhythmogenic events associated with contractile dysfunction and finally in heart failure after persistent stress activation in ACT patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available